The data are in! Unimolecular multiagonists have demonstrated efficacy by concurrent activation of hormone receptors that affect energy homeostasis. Learn how emerging agents offer robust glucose control, with a low risk of hypoglycemia, as well as weight loss. This activity is a compilation of the highlights of satellite symposia originally presented live at ADA’s 82nd Scientific Sessions and ENDO 2022
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows, nurse practitioners, and physician assistants engaged in the care of patients with T2D.
- Plan strategies to address unmet needs, including treatment initiation and escalation, for diverse patient populations with T2D
- Assess the clinical implications of emerging evidence regarding the incretin effect and the roles of GLP-1 and GIP
- Relate the pathophysiology of GLP-1 and GIP to potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
- Evaluate and interpret the implications of efficacy and safety data of novel dual agonists for T2D
- Addressing unmet needs in T2D
- Delineating the incretin effect and the roles of GLP-1 and GIP
- Potential benefits of agonism of multiple receptors that affect energy homeostasis
- Clinical implications of tirzepatide efficacy and safety data
- Recap of key points
The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this activity is not intended to provide extensive training or certification in the field.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until July 10, 2023. PAs should only claim credit commensurate with the extent of their participation.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
Medical Learning Institute, Inc., and Endocrine Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
Chief, Division of Endocrinology and Metabolis m
Duke University School of Medicine
Professor of Medicine
Department of Internal Medicine/ Endocrinology
Department of Population and Data Sciences
Medical Director, Office of Clinical Trials Management
UT Southwestern Medical Center
Pennington Biomedical Research Center
Baton Rouge, LA
Currently, Dr. Ryan serves as Past President of the World Obesity Federation, Co-Chair of the SELECT Steering Committee and member of the Data Safety Monitoring Board for setmelanotide. She has more than 300 publications and remains an active consultant and advisor to companies developing drugs, devices, lifestyle programs and medical approaches to obesity management.
Diabetes Division, St. Josef Hospital
Bertram Award (1993), the Werner Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the German Diabetes Association.
Juan Pablo Frias, MD, Velocity Clinical Research, Los Angeles, CA
Juan Pablo Frias, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi; Research Grant from Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi; Speakers’ Bureau with Lilly, Merck, and Sanofi.
David A. D’Alessio, MD, Duke University School of Medicine, Durham, NC
David A. D’Alessio, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Lilly and Sun Pharma; Research Grant from Lilly and Merck.
Ildiko Lingvay, MD, MPH, MSCS, UT Southwestern Medical Center, Dallas, TX
Ildiko Lingvay, MD, MPH, MSCS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for AstraZeneca, Bayer, Intarcia, Intercept, Lilly, and Merck;
The following relationships have ended within the last 24 months: Advisory Board/Consultant for Boehringer Ingelheim, Novo Nordisk, and Sanofi; Research Grant from Boehringer Ingelheim, Merck/Pfizer, Mylan, Novo Nordisk, and Sanofi.
Donna Ryan, MD, Pennington Biomedical Research Center, Baton Rouge, LA
Donna Ryan, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Altimmune, Amgen, Calibrate, Epitomee, Gila, Lilly, Novo Nordisk, Roman, Scientific Intake, Wondr Health, Xeno Bioscience, YSOPIA, and Zealand; Speakers’ Bureau with Novo Nordisk; Other: Stock Options with Calibrate, Epitomee, Roman, and Scientific Intake. On Data Safety Monitoring Board for Rhythm. Co-chair of steering committee for the SELECT Trial for Novo Nordisk.
Michael A. Nauck, MD, St. Josef Hospital, Ruhr University, Bochum, Germany
Michael A. Nauck, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Boehringer Ingelheim, Gasherbrum, Inventiva, Lilly, Merck Sharp & Dohme Corp., Novo Nordisk, Pfizer, Sanofi, and Servier;
The following relationships have ended within the last 24 months: Advisory Board/Consultant for AstraZeneca, Berlin-Chemie, and Regor Therapeutics.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Once submitted, the certificate will be automatically generated as a PDF online.
This activity is supported by an educational grant from Lilly.
About this Activity